Can 18F-fluorodeoxyglucose positron emission tomography predict responses to neoadjuvant therapy in oesophageal cancer patients? A meta-analysis

Nuclear Medicine Communications

Volumn 32, Issue 11, 2011, Pages 1005-1010

  Chen, Yu Mei ^a   Pan, Xu Feng ^b   Tong, Lin Jun ^a   Shi, Yi Ping ^a   Chen, Tao ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

emission computed; fluorodeoxyglucose; meta analysis neoadjuvant therapy; oesophageal neoplasm; tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL ASSESSMENT TOOL; DIAGNOSTIC VALUE; EMBASE; ESOPHAGUS CANCER; HUMAN; MEDLINE; META ANALYSIS; METHODOLOGY; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PROGNOSIS; PUBLICATION; QUALITY CONTROL; SENSITIVITY AND SPECIFICITY; STANDARD; TREATMENT DURATION; TREATMENT RESPONSE; ADENOCARCINOMA; ADJUVANT THERAPY; AREA UNDER THE CURVE; CONFIDENCE INTERVAL; ESOPHAGUS TUMOR; RECEIVER OPERATING CHARACTERISTIC; RISK; SCINTISCANNING;

ADENOCARCINOMA; AREA UNDER CURVE; CONFIDENCE INTERVALS; ESOPHAGEAL NEOPLASMS; FLUORODEOXYGLUCOSE F18; HUMANS; NEOADJUVANT THERAPY; ODDS RATIO; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 80053574776     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e32834a8366     Document Type: Article

References (25)

1. Altekruse SF, Kosary CL, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2007, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/ 1975-2007/, based on November 2009 SEER data submission, posted to the SEER website, 2010.
2. Herszényi L, Tulassay Z. Epidemiology of gastrointestinal and liver tumors. Eur Rev Med Pharmacol Sci 2010;14:249-258.
3. Zhao P, Dai M, Chen W, Li N. Cancer trends in China. Jpn J Clin Oncol 2010; 40:281-285.
4. Hulscher JB, Tijssen JG, Obertop H, van Lanschot JJ. Transthoracic versus transhiatal resection for carcinoma of the esophagus: a meta-analysis. Ann Thorac Surg 2001; 72:306-313. (Pubitemid 32643075)
5. Schwaiger M, Peschel C. Biological imaging for selecting and monitoring cancer therapy; a pathway to individualised therapy. Eur J Nucl Med Mol Imaging 2006; 33 (Suppl 1):S1-S5.
6. Kelsen DP, Winter KA, Gunderson LL, Mortimer J, Estes NC, Haller DG, et al. Long term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J ClinOncol 2007; 25:3719-3725. (Pubitemid 47372613)
7. Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 2003; 3:25. Available from: http://www.biomed-central.com/1471-2288/3/25
8. Gould MK, Kuschner WG, Rydzak CE, Maclean CC, Demas AN Shigemitsu H, et al. Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small cell lung cancer: a meta-analysis. Ann Intern Med 2003; 139:879-892.
9. Zamora J, Abraira V, Muriel A, Khan K, Coomarasamy A. Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol 2006; 6:31.
10. Klaeser B, Nitzsche E, Schuller JC, Kö berle D, Widmer L, Balmer-Majno S, et al. Limited predictive value of FDG-PET for response assessment in the preoperative treatment of esophageal cancer: results of a prospective multicenter trial (SAKK 75/02). Onkologie 2009; 32:724-730.
11. Roedl JB, Halpern EF, Colen RR, Sahani DV, Fischman AJ, Blake MA. Metabolic tumor width parameters as determined on PET/CT predict disease-free survival and treatment response in squamous cell carcinoma of the esophagus. Mol Imaging Biol 2009; 11:54-60.
12. Roedl JB, Colen RR, Holalkere NS, Fischman AJ, Choi NC, Blake MA. Adenocarcinomas of the esophagus: response to chemoradiotherapy is associated with decrease of metabolic tumor volume as measured on PETCT: comparison to histopathologic and clinical response evaluation. Radiother Oncol 2008; 89:278-286.
13. Higuchi I, Yasuda T, Yano M, Doki Y, Miyata H, Tatsumi M, et al. Lack of fludeoxyglucose F 18 uptake in posttreatment positron emission tomography as a significant predictor of survival after subsequent surgery in multimodality treatment for patients with locally advanced esophageal squamous cell carcinoma. J Thorac Cardiovasc Surg 2008; 136:205-212, 212e1-212e3.
14. McLoughlin JM, Melis M, Siegel EM, Dean EM, Weber JM, Chern J, et al. Are patients with esophageal cancer who become PET negative after neoadjuvant chemoradiation free of cancer? J Am Coll Surg 2008; 206: 879-886. (Pubitemid 351620864)
15. Wieder HA, Ott K, Lordick F, Becker K, Stahl A, Herrmann K, et al. Prediction of tumor response by FDG-PET: comparison of the accuracy of single and sequential studies in patients with adenocarcinomas of the esophagogastric junction. Eur J Nucl Med Mol imaging 2007; 34: 1925-1932. (Pubitemid 350212130)
16. Port JL, Lee PC, Korst RJ, Liss Y, Meherally D, Christos P, et al. Positron emission tomographic scanning predicts survival after induction chemotherapy for esophageal carcinoma. Ann Thorac Surg 2007; 84: 393-400. (Pubitemid 47079022)
17. Kim MK, Ryu JS, Kim SB, Ahn JH, Kim SY, Park SI, et al. Value of complete metabolic response by (18)F-fluorodeoxyglucose-positron emission tomography in oesophageal cancer for prediction of pathologic response and survival after preoperative chemoradiotherapy. Eur J Cancer 2007; 43:1385-1391. (Pubitemid 46874075)
18. Mamede M, Abreu-E-Lima P, Oliva MR, NoséV, Mamon H, Gerbaudo VH. FDG-PET/CT tumor segmentation-derived indices of metabolic activity to assess response to neoadjuvant therapy and progression-free survival in esophageal cancer: correlation with histopathology results. Am J Clin Oncol 2007; 30:377-388. (Pubitemid 47356682)
19. Bruzzi JF, Swisher SG, Truong MT, Munden RF, Hofstetter WL, Macapinlac HA, et al. Detection of interval distant metastases: clinical utility of integrated CT-PET imaging in patients with esophageal carcinoma after neoadjuvant therapy. Cancer 2007; 109:125-134. (Pubitemid 46127202)
20. Ott K, Weber WA, Lordick F, Becker K, Busch R, Herrmann K, et al. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol 2006; 24:4692-4698. (Pubitemid 46646244)
21. Westerterp M, Omloo JM, Sloof GW, Hulshof MC, Hoekstra OS, Crezee H, et al. Monitoring of response to pre-operative chemoradiation in combination with hyperthermia in oesophageal cancer by FDG-PET. Int J Hyperthermia 2006; 22:149-160. (Pubitemid 43675162)
22. Cerfolio RJ, Bryant AS, Ohja B, Bartolucci AA, Eloubeidi MA. The accuracy of endoscopic ultrasonography with fine-needle aspiration, integrated positron emission tomography with computed tomography, and computed tomography in restaging patients with esophageal cancer after neoadjuvant chemoradiotherapy. J Thorac Cardiovasc Surg 2005; 129: 1232-1241. (Pubitemid 40804839)
23. Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma: clinicopathologic correlations. Cancer 1994; 73:2680-2686. (Pubitemid 24166250)
24. Japanese Society for Esophageal Diseases. Guidelines for the clinical and pathological studies on carcinoma of the esophagus. 1999; 9th ed. Tokyo: Kanehara ; 1999.
25. Kwee RM. Prediction of tumor response to neoadjuvant therapy in patients with esophageal cancer with use of 18F FDG PET: a systematic review. Radiology 2010; 254:707-717.